Witzel, Isabell <br/><br/>
Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial.  [electronic resource] 

 -  Breast cancer research and treatment  Sep 2010 
 - 437-45 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1573-7217 
<br/><br/><label>Standard No.: </label>10.1007/s10549-010-1030-9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Agents--therapeutic use<br/>Biomarkers, Tumor--blood<br/>Breast Neoplasms--blood<br/>Chemotherapy, Adjuvant<br/>Enzyme-Linked Immunosorbent Assay<br/>Female<br/>Germany<br/>Humans<br/>Middle Aged<br/>Neoadjuvant Therapy<br/>Neoplasm Staging<br/>Odds Ratio<br/>Receptor, ErbB-2--antagonists & inhibitors<br/>Time Factors<br/>Trastuzumab<br/>Treatment Outcome